Search results for Cidara Therapeutics

<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>

<![CDATA[Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics]]>

UCB inks $2B Candid buyout to join Gilead in autoimmune field

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio to challenge Gilead for an emerging opportunity for T-...

Sidewinder secures $137M to advance ‘precision’ ADCs

Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.

<![CDATA[Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement]]>

OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates

Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch of new investors. The San Diego startup has sunk its t...

UCB Joins the Chase for Immune System Reset With $2B Acquisition

Candid Therapeutics brings to UCB two clinical-stage T cell engagers in development for autoimmune disorders. To accept UCB’s offer, Candid terminated its reverse merger with Rally...

Cytospire hauls in $83M for a new type of T cell engager

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies. 

<![CDATA[Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement ]]>

CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with pers...

Chasing a tough-to-treat lung disease, Avalyn plans an IPO

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior versions of entrenched — but flawed — medicines for idio...

Two New Takes on Making a Type of Targeted Cancer Therapy Even Better

Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer...

Calliditas?

Calliditas? Anonymous (not verified) Fri, 04/24/2026 - 11:14 field_thread_url https://cafepharma.com/boards/threads/calliditas.661472/ b...

Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials

Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera The...

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Angelini Pharma’s $4B Acquisition Adds Rare Disease Drugs to a Global Growth Strategy

Angelini Pharma’s acquisition of Catalyst Pharmaceuticals is part of a transformation strategy focused on neurological medicines. Catalyst’s top product is Firdapse, the first FDA-...

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple cancer medicines already in clinical testing.

<![CDATA[Angelini Pharma Enters $ 4.1 Billion Agreement to Acquire Catalyst Pharmaceuticals ]]>

Angelini to buy Catalyst in $4B play for rare neuro drugs

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

<![CDATA[Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava]]>

Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition

KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angio...

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics

Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financin...